MEDICINOVA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MEDICINOVA, INC. (MNOV) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $176.77 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $176.77K, a 13.73% decline year-over-year.
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $407.76K, a 42.60% increase year-over-year.
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $157.69K, a 68.77% decline year-over-year.
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $204.90K, a 1.23% decline year-over-year.
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $829.10K, a 30.43% decline from fiscal 2024.
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.19M, a 67.68% increase from fiscal 2023.
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $710.71K, a 10.61% increase from fiscal 2022.
- MEDICINOVA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $642.52K, a 62.59% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $176.77K 10-Q · filed 2026-08-13 | $584.53K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $407.76K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $829.10K 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $157.69K 10-Q · filed 2025-11-12 | $362.59K derived: sum of 2 quarters · filed 2026-08-13 | $648.53K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $204.90K 10-Q · filed 2026-08-13 | $490.84K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $285.94K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $1.19M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $504.86K 10-Q · filed 2025-11-12 | $712.32K derived: sum of 2 quarters · filed 2025-11-12 | $927.75K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $207.46K 10-Q · filed 2025-11-12 | $422.88K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $215.43K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $710.71K 10-K · filed 2025-02-19 | |||
| 2023-09-30 | $219.14K 10-Q · filed 2024-11-13 | $544.85K derived: sum of 2 quarters · filed 2024-11-13 | $948.12K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $325.71K 10-Q · filed 2024-11-13 | $728.97K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $403.26K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $642.52K 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $158.30K 10-Q · filed 2023-11-09 | $432.80K derived: sum of 2 quarters · filed 2023-11-09 | $513.85K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $274.50K 10-Q · filed 2023-11-09 | $355.56K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $81.05K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $1.72M 10-K/A · filed 2023-03-28 | |||
| 2021-09-30 | $578.94K 10-Q · filed 2022-11-10 | $1.33M derived: sum of 2 quarters · filed 2022-11-10 | $2.47M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $755.90K 10-Q · filed 2022-11-10 | $1.90M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $1.14M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $3.18M 10-K · filed 2022-02-16 | |||
| 2020-09-30 | $1.03M 10-Q · filed 2021-11-12 | $2.18M derived: sum of 2 quarters · filed 2021-11-12 | $2.78M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $1.15M 10-Q · filed 2021-11-12 | $1.74M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $596.38K 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $4.11M 10-K · filed 2021-02-19 | |||
| 2019-09-30 | $373.84K 10-Q · filed 2020-10-26 | $2.22M derived: sum of 2 quarters · filed 2020-10-26 | $4.92M derived: sum of 3 quarters · filed 2020-10-26 | |
| 2019-06-30 | $1.84M 10-Q · filed 2020-10-26 | $4.54M derived: sum of 2 quarters · filed 2020-10-26 | ||
| 2019-03-31 | $2.70M 10-Q · filed 2020-10-26 | |||
| 2018-12-31 | $6.33M 10-K · filed 2020-02-13 | |||
| 2004-12-31 | $34.07M 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |